**FIGURE 1** Study flow and follow-up

*V1 to V4: visits 1 is day 1, V2 is phone call after 1 week, V3 is visit after 3 months, V4 is visit after 1 year of start treatment with HDM SLIT-tablet; after study completion patients were asked if they intended to continue treatment after the study; N is number of patients; AEs is adverse events. Percentages represent proportion of patients that were included (N=415) in the study.*

**FIGURE 2** CARAT scores per visit and per allergic rhinitis and asthma status

A picture containing text, screenshot, line, diagram

Description automatically generated

A

*A picture containing text, screenshot, line, diagram

Description automatically generatedA picture containing text, screenshot, line, diagram

Description automatically generated*

B

C

*CARAT is combined allergic rhinitis and asthma test; V is visit; MCID is minimal clinical important difference. Dotted line indicates MCID of +4 points compared to baseline. All patients (A); patients with rhinitis but without asthma (B); patients with Allergic rhinitis and asthma (C).*